We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMEA: Contrast Agents Associated With Kidney Risk
EMEA: Contrast Agents Associated With Kidney Risk
December 17, 2009
Manufacturers of contrast agents containing gadolinium that are used for magnetic resonance scans are being asked to revise the drug labeling to warn of
the risk of developing nephrogenic systemic fibrosis (NSF), the European Medicines Agency (EMEA) says.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor